Rising Prevalence of Various Disorders to Create Scope for the US Interleukin Inhibitors Market Growth

The US Interleukin Inhibitors market is anticipated to grow significantly at a CAGR of 11.0% over the forecast period (2021-2027). The key aspect that drives the growth of the US Interleukin Inhibitors market includes the rise in the prevalence of arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. According to the Institute for Health Metrics and Evaluation, the prevalence of psoriasis was 4.1 million in 2017 which increased to 4.2 million in 2019. The prevalence of inflammatory bowel disease (IBD) was more than 749,000 which increased to more than 762,000 in 2019. 

Browse the full report description US Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/us-interleukin-inhibitors-market

Whereas, the prevalence of asthma was 32.6 million in 2017 which increased to 33.9 million in 2019. The rise in the prevalence of such diseases demands for advanced treatment options including interleukin inhibitors, which, in turn, drives the growth of the market. Further, the presence of the key market players operating in the market also drives the growth of the market in the country over the forecast period. Players such as Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among others contribute to the growth of the market across the country by adopting various growth strategies.

Market Coverage

• Market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- By Product Type and Applications
• Country Covered- the US
• Competitive Landscape- Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in base year?
• Which segment will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

US Interleukin Inhibitors Market – Segmentation

By Product Type

• IL-1 Inhibitors
• IL-5 Inhibitors
• IL-6 Inhibitors
• IL-17 Inhibitors
• IL-23 Inhibitors

By Applications

• Arthritis
• Asthma
• Eczema
• Inflammatory Bowel Disease (IBD)
• Psoriasis
• Others